Drugs / DS-1055a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04419532 | Oct 2020 → Jul 2027 expected | metastatic neoplasm, neoplasm | Daiichi Sankyo | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-1055a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04419532 ↗ |
| Route | Intravenous | “Administered as an intravenous infusion on Day 1 of every 21-day cycle following low dose administration(s) in priming dose period.” NCT04419532 ↗ |